Chelating agents: succimer, edetate calcium and deferoxamine safety

Remember that chelation does not fix the exposure

Chelation removes metal already in the body, but it cannot protect a child who returns to the same lead source. The succimer label directs clinicians to identify and eliminate the lead source before beginning treatment, and CDC guidance pairs very high blood lead levels with an environmental investigation and a lead-safe home before discharge.

Blood lead can rebound after a course as lead stored in bone moves back into the blood, so follow-up testing is part of treatment. Ask about peeling paint, renovation, imported products and caregivers' occupations. Discuss nutrition with a focus on iron and calcium, which CDC recommends, and link families to support programmes where appropriate.

Chelation is reserved for very high blood lead levels and is planned with a medical toxicologist or a paediatrician experienced in lead management. For lower levels, the core interventions are finding and removing the source, nutrition and scheduled repeat testing, so a chelating drug is not the expected answer for every child with a raised level.

Monitor succimer for blood, liver and skin effects

Succimer is an oral chelator used for children with significantly elevated blood lead. It is not the treatment for lead encephalopathy, which needs parenteral chelation in hospital. Capsule contents can be sprinkled on a small amount of soft food for young children who cannot swallow capsules, and the full course is completed as prescribed.

The label calls for blood counts and liver enzymes during treatment, assessment of kidney function and adequate hydration. Report fever, sore throat or other signs of infection, which may reflect neutropenia, and any rash, including mucocutaneous blistering. Check that no other chelator has been given at the same time unless the prescriber has deliberately combined them. Teach caregivers to report vomiting that prevents doses being kept down, because missed doses can leave the course incomplete.

Protect against the edetate name confusion

Edetate calcium disodium is given parenterally for severe lead poisoning, sometimes combined with dimercaprol when encephalopathy is present. It is easily confused with edetate disodium, a different product that can cause dangerous hypocalcaemia. Check the full drug name carefully at every step, and treat any mismatch between order and product as a stop-and-clarify moment.

Confirm adequate urine flow before treatment begins, because lead is excreted through the kidneys and renal injury and proteinuria are possible adverse effects. Track intake and output, renal function and neurological status. A child with lead encephalopathy is critically unwell; seizure precautions and close neurological observation sit alongside the chelation plan.

Expect red urine but watch hearing, vision and infection with deferoxamine

Deferoxamine binds iron in patients with chronic transfusional iron overload and in acute iron poisoning. The iron complex can turn urine reddish, an expected finding that families should be told about in advance. Rapid IV infusion can cause flushing, urticaria, hypotension and shock, so infusion rate follows the order and protocol precisely.

With prolonged high-dose use, hearing and vision can be affected, so periodic hearing and eye checks are recommended. Children may show slowed growth. Deferoxamine increases vulnerability to Yersinia and mucormycosis infections; report fever, abdominal pain or diarrhoea. Kidney function needs monitoring, and vitamin C should only be taken if the prescriber approves it.

Work a hypothetical deferoxamine question

Imagine a hypothetical 10-year-old with thalassaemia receiving a deferoxamine infusion whose parent reports that the urine has turned reddish-orange. Options include stopping the infusion and calling the rapid response team, reassuring the parent that this colour change is expected while continuing to assess, or sending urine to look for haemolysis. Reassuring and continuing assessment is strongest because the change reflects excreted iron.

Stopping the infusion would interrupt needed therapy without evidence of harm. Investigating haemolysis would be reasonable only if other findings suggested it. The answer changes if the child develops flushing, hives or hypotension during the infusion, which points to an infusion reaction requiring the rate or infusion to be stopped and the prescriber informed.

Sources and further reading

DailyMed: Chemet (succimer) capsule label. Eliminating the lead source, blood count and liver monitoring, hydration, rash, sprinkling capsule contents and blood lead rebound.

DailyMed: Deferoxamine mesylate injection label. Reddish urine, rapid infusion reactions, ocular and auditory toxicity, Yersinia and mucormycosis, renal effects, growth and vitamin C.

MSD Manual Professional: Lead Poisoning. Choice of succimer, dimercaprol and calcium disodium EDTA, confusion with disodium EDTA, urine flow and renal monitoring, source removal.

CDC: Clinical guidance for lead exposure in children. Chelation for very high levels with expert consultation, environmental investigation, follow-up testing and iron and calcium nutrition.